MEP24008A - Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds - Google Patents

Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

Info

Publication number
MEP24008A
MEP24008A MEP-240/08A MEP24008A MEP24008A ME P24008 A MEP24008 A ME P24008A ME P24008 A MEP24008 A ME P24008A ME P24008 A MEP24008 A ME P24008A
Authority
ME
Montenegro
Prior art keywords
carnitine
alkanoyl
esters
active compounds
pharmacologically active
Prior art date
Application number
MEP-240/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Claudio Pisano
Maria Ornella Tinti
Mose Santaniello
Luciana Critelli
Giovanni Salvatori
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MEP24008A publication Critical patent/MEP24008A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
MEP-240/08A 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds MEP24008A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999RM000220A IT1306129B1 (it) 1999-04-13 1999-04-13 Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
YUP-702/01A RS50911B (sr) 1999-04-13 2000-04-11 Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja
PCT/IT2000/000137 WO2000061543A2 (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines

Publications (1)

Publication Number Publication Date
MEP24008A true MEP24008A (en) 2010-06-10

Family

ID=11406659

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-240A ME00113B (me) 1999-04-13 2000-04-11 Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja
MEP-240/08A MEP24008A (en) 1999-04-13 2000-04-11 Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2008-240A ME00113B (me) 1999-04-13 2000-04-11 Estri l-karnitina ili alkanoil l-karnitina korisni kao katjonski lipidi za unutarćelijsko oslobađanje farmakološki aktivnih jedinjenja

Country Status (34)

Country Link
US (4) US6797281B1 (xx)
EP (3) EP1435232A1 (xx)
JP (2) JP4703855B2 (xx)
KR (2) KR100684378B1 (xx)
CN (2) CN1263730C (xx)
AT (2) ATE317257T1 (xx)
AU (2) AU776301B2 (xx)
BG (3) BG65501B1 (xx)
BR (2) BRPI0017460B1 (xx)
CA (2) CA2650202C (xx)
CZ (1) CZ302628B6 (xx)
DE (2) DE60025961T2 (xx)
DK (2) DK1183228T3 (xx)
EA (2) EA006021B1 (xx)
EE (2) EE05514B1 (xx)
ES (2) ES2258688T3 (xx)
HK (2) HK1045145B (xx)
HR (1) HRP20010740B1 (xx)
HU (1) HU229366B1 (xx)
IL (4) IL145765A0 (xx)
IS (2) IS2476B (xx)
IT (1) IT1306129B1 (xx)
ME (2) ME00113B (xx)
MX (1) MXPA01010359A (xx)
NO (2) NO327742B1 (xx)
NZ (2) NZ515270A (xx)
PL (2) PL204418B1 (xx)
PT (2) PT1426044E (xx)
RS (3) RS52682B (xx)
SI (2) SI1426044T1 (xx)
SK (2) SK287253B6 (xx)
TR (2) TR200202358T2 (xx)
WO (1) WO2000061543A2 (xx)
ZA (1) ZA200109291B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246792B1 (en) * 2000-01-13 2014-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE10113446A1 (de) † 2001-03-19 2002-09-26 Schwarzkopf Gmbh Hans Haarbehandlungsmittel mit Betainen
PT2108362E (pt) * 2002-06-26 2013-07-11 Medigene Ag Preparação lipossomal catiónica que compreende um taxano
ES2331791T5 (es) 2002-06-26 2016-01-21 Medigene Ag Método de producción de una preparación catiónica de liposomas que comprende un compuesto lipófilo
ITRM20040288A1 (it) * 2004-06-11 2004-09-11 Sigma Tau Ind Farmaceuti Uso della 7-t-butossiimminometilcamptotecina per la preparazione di un medicamento per il trattamento delle neoplasie dell'utero.
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
WO2006094203A1 (en) * 2005-03-02 2006-09-08 Northeastern University Mitochondriotropic phospholipid vesicles
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
EP1915132A1 (en) * 2005-08-10 2008-04-30 Novartis AG Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin
MX2008001970A (es) * 2005-08-10 2008-03-24 Novartis Ag Formulaciones para 7-(t-butoxi)iminometil camptotecin.
US20100178325A1 (en) * 2006-08-23 2010-07-15 Biodelivery Sciences International, Inc. Amphiphilic nucleotide cochleate compositions and methods of using the same
KR20090115856A (ko) * 2007-02-01 2009-11-09 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 캄포테신 유도체를 함유하는 약학적 조성물
WO2008101173A2 (en) * 2007-02-16 2008-08-21 Cornell University Biodegradable compositions and materials
US20100204432A1 (en) * 2007-05-28 2010-08-12 Husam Younes Biodegradable elastomers prepared by the condensation of an organic di-, tri- or tetra-carboxylic acid and an organic diol
CN103450077B (zh) 2007-06-08 2016-07-06 满康德股份有限公司 IRE-1α抑制剂
EP2265645A4 (en) * 2008-03-13 2011-03-23 Perkinelmer Health Sci Inc ENZYMATIC SUBSTRATES FOR MULTIPLE DETECTION SYSTEMS
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013032643A2 (en) * 2011-08-31 2013-03-07 Dicerna Pharmaceuticals, Inc. Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells
US20140274798A1 (en) 2013-03-15 2014-09-18 University Of Washington Through Its Center For Commercialization Compounds and methods relating to lysosomal storage disorders
MX2018010586A (es) 2016-03-02 2019-03-28 Univ Texas Nanovacuna de activacion de "sting" para inmunoterapia.
US11103588B2 (en) 2017-06-06 2021-08-31 Wayne State University Methods and compositions relating to carnitine-derived materials
CN115177608B (zh) * 2022-07-26 2023-12-05 南方医科大学南方医院 长链酰基肉碱类化合物在制备预防和/或治疗肝癌的药物中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866040A (en) * 1986-01-06 1989-09-12 Alfred Stracher Aminocarnitine directed pharmaceutical agents
US5008288A (en) * 1986-01-06 1991-04-16 Alfred Stracher Carnitine directed pharmaceutical agents
IT1230142B (it) * 1989-05-03 1991-10-14 Fidia Spa Derivati della carnitina, processo per la loro preparazione e impiego in terapia umana
AU660417B2 (en) * 1990-06-15 1995-06-29 University Of North Carolina At Chapel Hill, The Ether lipid-nucleoside covalent conjugates
IT1248321B (it) * 1991-05-15 1995-01-05 Sigma Tau Ind Farmaceuti Uso di esteri di acil l-carnitine con l'acido gamma-idrossibutirrico per produrre composizioni farmaceutiche per il trattamento di epatopatie
IT1258370B (it) * 1992-03-02 1996-02-26 Sigma Tau Ind Farmaceuti Esteri della l-carnitina e di acil l-carnitine dotati di attivita' miorilassante selettiva sull'apparato gastro-intestinale e composizioni farmaceutiche che li contengono.
US5972600A (en) * 1992-04-03 1999-10-26 The Regents Of The University Of California Separation of active complexes
IT1263013B (it) * 1992-10-20 1996-07-23 Avantgarde Spa Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
US5512671A (en) * 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
IT1261984B (it) * 1993-06-22 1996-06-11 Avantgarde Spa Uso di esteri della l-carnitina o di acil l- carnitine con idrossiacidi per produrre composizioni farmaceutiche per il trattamento di affezioni cutanee.
DE69407292T2 (de) * 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen
IT1273987B (it) * 1994-09-29 1997-07-14 Sigma Tau Ind Farmaceuti Uso di esteri ftalidilidenici della carnitina e di alcanoil carnitine per il trattamento dello shock endotossico
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6316652B1 (en) * 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
EP0833667A4 (en) * 1995-06-07 2001-11-21 Univ California STABILIZATION OF POLYNUCLEOTIDE COMPLEXES
IT1283955B1 (it) * 1996-03-20 1998-05-07 Sigma Tau Ind Farmaceuti Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria.
WO1998004720A1 (en) * 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6071532A (en) * 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
IT1299172B1 (it) * 1998-05-06 2000-02-29 Sigma Tau Ind Farmaceuti Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti

Also Published As

Publication number Publication date
DK1183228T3 (da) 2005-05-17
EA200101076A1 (ru) 2002-04-25
DE60025961T2 (de) 2006-08-17
BG109876A (en) 2008-02-29
BR0009765B1 (pt) 2013-11-05
TR200102941T2 (tr) 2002-05-21
HRP20010740B1 (en) 2005-08-31
CA2370143C (en) 2011-06-21
YU70201A (sh) 2004-07-15
BG65312B1 (bg) 2008-01-31
KR20010113794A (ko) 2001-12-28
EA200300745A1 (ru) 2003-12-25
DE60025961D1 (de) 2006-04-20
PL204418B1 (pl) 2010-01-29
IL175366A (en) 2010-12-30
US7585519B2 (en) 2009-09-08
SI1426044T1 (sl) 2006-04-30
IS2539B (is) 2009-09-15
CZ302628B6 (cs) 2011-08-10
KR20060113799A (ko) 2006-11-02
ES2234591T3 (es) 2005-07-01
CA2650202A1 (en) 2000-10-19
ES2258688T3 (es) 2006-09-01
IL175366A0 (en) 2006-09-05
RS50911B (sr) 2010-08-31
BR0009765A (pt) 2002-01-02
IT1306129B1 (it) 2001-05-30
AU2004224958B2 (en) 2007-11-22
KR100684378B1 (ko) 2007-02-20
DE60017388T2 (de) 2006-03-30
RS20090448A (xx) 2010-06-30
US6797281B1 (en) 2004-09-28
EE05719B1 (et) 2014-08-15
SI1183228T1 (en) 2005-04-30
EE201100028A (et) 2011-08-15
EP1426044A1 (en) 2004-06-09
EP1426044B1 (en) 2006-02-08
BRPI0017460B1 (pt) 2016-04-19
EE200100518A (et) 2002-12-16
SK287253B6 (sk) 2010-04-07
US20050079209A1 (en) 2005-04-14
NO20085413L (no) 2001-10-12
JP4703855B2 (ja) 2011-06-15
HK1045145A1 (en) 2002-11-15
BG105971A (en) 2002-08-30
DK1426044T3 (da) 2006-06-12
NZ515270A (en) 2004-02-27
PL351112A1 (en) 2003-03-24
ME00113B (me) 2010-10-10
US7629003B2 (en) 2009-12-08
EP1183228B1 (en) 2005-01-12
HRP20010740A2 (en) 2002-10-31
PL211710B1 (pl) 2012-06-29
EA006021B1 (ru) 2005-08-25
AU4312300A (en) 2000-11-14
JP2011042657A (ja) 2011-03-03
PT1183228E (pt) 2005-04-29
HUP0201446A3 (en) 2002-11-28
CN1263730C (zh) 2006-07-12
CN1823731A (zh) 2006-08-30
ATE317257T1 (de) 2006-02-15
IL145765A0 (en) 2002-07-25
TR200202358T2 (tr) 2002-12-23
HK1045145B (zh) 2006-01-27
IS2476B (is) 2008-12-15
ITRM990220A1 (it) 2000-10-13
HUP0201446A2 (en) 2002-08-28
EE05514B1 (et) 2012-02-15
NO336949B1 (no) 2015-11-30
PT1426044E (pt) 2006-06-30
NZ528874A (en) 2005-09-30
BG65501B1 (bg) 2008-10-31
WO2000061543A3 (en) 2001-01-11
HK1092732A1 (en) 2007-02-16
US20070190128A1 (en) 2007-08-16
NO20014985D0 (no) 2001-10-12
AU2004224958A1 (en) 2004-11-25
IS6095A (is) 2001-09-28
NO327742B1 (no) 2009-09-14
MXPA01010359A (es) 2002-05-06
US20040186175A1 (en) 2004-09-23
KR100798499B1 (ko) 2008-01-28
EA004459B1 (ru) 2004-04-29
CA2370143A1 (en) 2000-10-19
ZA200109291B (en) 2002-08-16
CZ20013617A3 (cs) 2002-02-13
IS8719A (is) 2008-03-07
ATE286873T1 (de) 2005-01-15
IL145765A (en) 2007-07-04
EP1183228A2 (en) 2002-03-06
CN100402017C (zh) 2008-07-16
AU776301B2 (en) 2004-09-02
RS52682B (en) 2013-08-30
WO2000061543A2 (en) 2000-10-19
SK288246B6 (sk) 2015-03-03
JP2002541238A (ja) 2002-12-03
DE60017388D1 (de) 2005-02-17
CA2650202C (en) 2012-12-11
NO20014985L (no) 2001-10-12
IL185486A0 (en) 2008-01-06
HU229366B1 (en) 2013-11-28
SK14312001A3 (sk) 2002-02-05
CN1359370A (zh) 2002-07-17
EP1435232A1 (en) 2004-07-07
JP5420507B2 (ja) 2014-02-19

Similar Documents

Publication Publication Date Title
MEP24008A (en) Esters of l-carnitine or alkanoyl l-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
AR031975A1 (es) Compuestos analogos de (1r,cis)-4-(6-amino-9h-purin-9-il) -2-ciclopenteno-1-metanol, proceso para su preparacion, su uso en el tratamiento de infecciones virales, y envase que los contiene
ES2192789T3 (es) Derivados de hidrazono-benzazuleno, composiciones farmaceuticas y compuestos intermedios.
DE60003074D1 (de) Fusidinsäure-derivate
IT1299172B1 (it) Esteri perfluorurati di alcanoil l-carnitine utilizzabili quali lipidi cationici per l'immissione intracellulare di composti
CA2390631A1 (en) Carboxamide-substituted benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions